ACELYRIN, INC. Reports Second Quarter 2023 Financial
ACELYRIN reported Phase 2b/3 trial data for izokibep showing early improvements in Hidradenitis Suppurativa patients, with Part B results expected Q3 2023. Psoriatic Arthritis trial enrollment completed, top-line data accelerated to Q1 2024. Strong cash position of $823M supports clinical programs. Leadership updates include Ken Lock as Chief Commercial Officer.
Reference News
ACELYRIN, INC. Reports Second Quarter 2023 Financial
ACELYRIN reported Phase 2b/3 trial data for izokibep showing early improvements in Hidradenitis Suppurativa patients, with Part B results expected Q3 2023. Psoriatic Arthritis trial enrollment completed, top-line data accelerated to Q1 2024. Strong cash position of $823M supports clinical programs. Leadership updates include Ken Lock as Chief Commercial Officer.